Evidence map›Paper›PMID 38473327›Full record

ReviewCancers2024

What Is the Role of Minimally Invasive Liver Surgery in Treating Patients with Hepatocellular Carcinoma on Cirrhosis?

Alessandro Vitale, Roberta Angelico, Bruno Sensi, Quirino Lai, Emanuele Kauffmann, Irene Scalera, Matteo Serenari, Michael Ginesini, Pierluigi Romano, Alessandro Furlanetto and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Alessandro VitaleDepartment of Surgical Oncological and Gastroenterological Sciences, Padua University, 35122 Padua, Italy.ORCID 0000-0002-4548-8308
Roberta AngelicoTransplant and HPB Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-3439-7750
Bruno SensiTransplant and HPB Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.
Quirino LaiGeneral Surgery and Organ Transplantation Unit, AUO Policlinico I of Rome, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-1487-3235
Emanuele KauffmannDivision of General and Transplant Surgery, Pisa University, 56126 Pisa, Italy.
Irene ScaleraUnità di Chirurgia Epatobiliare e Trapianti di Fegato, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy.ORCID 0000-0002-4244-9311
Matteo SerenariGeneral Surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Michael GinesiniDivision of General and Transplant Surgery, Pisa University, 56126 Pisa, Italy.ORCID 0000-0003-2224-9037
Pierluigi RomanoDepartment of Surgical Oncological and Gastroenterological Sciences, Padua University, 35122 Padua, Italy.ORCID 0000-0003-1810-0977
Alessandro FurlanettoDepartment of Surgical Oncological and Gastroenterological Sciences, Padua University, 35122 Padua, Italy.
Francesco D'AmicoUnità di Chirurgia Epatobiliare e Trapianti di Fegato, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy.ORCID 0000-0001-6915-9755
Italian Chapter of IHPBA (AICEP, Associazione Italiana di Chirurgia Epatobilio-Pancreatica)
University of Padua · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · ITUniversity of Pisa · ITUniversity of Rome Tor Vergata · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Minimally invasive liver surgery (MILS) has been slowly introduced in the past two decades and today represents a major weapon in the fight against HCC, for several reasons. This narrative review conveys the major emerging concepts in the field. The rise in metabolic-associated steatotic liver disease (MASLD)-related HCC means that patients with significant cardiovascular risk will benefit more profoundly from MILS. The advent of efficacious therapy is leading to conversion from non-resectable to resectable cases, and therefore more patients will be able to undergo MILS. In fact, resection outcomes with MILS are superior compared to open surgery both in the short and long term. Furthermore, indications to surgery may be further expanded by its use in Child B7 patients and by the use of laparoscopic ablation, a curative technique, instead of trans-arterial approaches in cases not amenable to radiofrequency. Therefore, in a promising new approach, multi-parametric treatment hierarchy, MILS is hierarchically superior to open surgery and comes second only to liver transplantation.

Indexed as

hepatocellular carcinomalaparoscopic ablationliver transplantationminimally invasive liver resectionmulti-parametric treatment hierarchy approach

Identifiers

PMID38473327
PMCPMC10930835
OpenAlexW4392240302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.